Aliskiren
- Generic Name
- Aliskiren
- Brand Names
- Rasilez, Tekturna, Tekturna Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C30H53N3O6
- CAS Number
- 173334-57-1
- Unique Ingredient Identifier
- 502FWN4Q32
- Background
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
- Indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1254
- Registration Number
- NCT00797862
- Locations
- 🇻🇪
Investigative Site, Caracas, Venezuela
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 860
- Registration Number
- NCT00787605
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 39
- Registration Number
- NCT00768040
- Locations
- 🇺🇸
Retinal Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Elman Retina Group, Baltimore, Maryland, United States
🇺🇸Vitreo-Retinal Associates, Grand Rapids, Michigan, United States
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 256
- Registration Number
- NCT00765947
- Locations
- 🇸🇰
Investigative Site, Bratislava, Slovakia
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1191
- Registration Number
- NCT00765674
- Locations
- 🇹🇷
Investigative Site, Ankara, Turkey
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 451
- Registration Number
- NCT00760266
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2008-08-12
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00732407
Aliskiren and Muscle Sympathetic Nerve Activity
- Conditions
- Interventions
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2010-01-14
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 30
- Registration Number
- NCT00719316
- Locations
- 🇳🇱
University Medical Center utrecht, Utrecht, Netherlands
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 564
- Registration Number
- NCT00667719
- Locations
- 🇹🇷
Investigative Site, Turkey, Turkey
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00660309
- Locations
- 🇺🇸
Novartis Investigator Site, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.